EBGLYSS® (Lebrikizumab) Receives Positive CHMP Opinion for Moderate-to-Severe Atopic Dermatitis

Almirall S.A. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending the marketing authorization of EBGLYSS for the treatment of adult and adolescent patients with moderate-to-severe atopic dermatitis, who are candidates for systemic therapy.
[Almirall, S.A.]
Press Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News